SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant volatility as investors digest the failure of the BlueBird 7 satellite to reach its intended orbit during a Blue Origin mission, though the community remains divided between those bracing for a sharp sell-off and those viewing the dip as a strategic buying opportunity. While the company confirmed insurance will cover the financial loss and reaffirmed its long-term deployment goals, market participants are heavily debating the reliability of launch providers, the impact of project delays, and the company's reliance on external partners for its upcoming constellation buildout.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is currently driving significant community activity due to a low-float setup and speculative hype surrounding a presidential executive order aimed at fast-tracking psychedelic research for veteran mental health. Traders are closely monitoring for a potential short squeeze, though skeptical voices in the community warn of a 'buy-the-rumor' sell-off and potential volatility associated with micro-cap biotech momentum plays.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is seeing significant market focus following the announcement of commercial yttrium metal production at its UK facility and a strategic investment in French processor Carester, bolstering the firm's non-China supply chain narrative. Investors are actively debating the impact of these developments against potential short-term dilution and the broader macro sensitivity of critical mineral stocks to government policy and trade tensions.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor attention driven by strong bullish sentiment surrounding its lead asset, CAN-2409, and anticipation of upcoming data releases at the American Urological Association annual meeting. The community is actively discussing the potential for a significant squeeze on high short interest, while supporters emphasize the company's robust balance sheet and long-term value potential in the oncology space.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing heightened market attention following a volatile leadership transition that includes the departure of its CEO and a strategic pivot to 'Fermi 2.0,' which has sparked intense debate among retail investors over whether the shakeup signals a disastrous collapse or a necessary step to secure a major AI data center tenant. While some community members worry about the lack of revenue and the potential for further downside, others view the current price as a long-term opportunity, pointing to the company's aggressive infrastructure expansion and the involvement of high-profile executive talent as evidence of its long-term viability.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is drawing significant attention as investors react to reports of a custom AI chip collaboration with Google, marking a potential shift toward deeper hyperscaler integration. While some community members highlight the stock's recent rapid gains and extended valuation as a sign of caution, bulls remain focused on the company's expanding role in AI infrastructure and custom ASIC production.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as retail investors ramp up activity ahead of the upcoming AACR conference, where new data for its SLS009 platform will be presented. The community is actively debating the potential for a short squeeze fueled by heavy call option positioning and large-scale short interest, while long-term supporters remain focused on the clinical potential of the GPS trial.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to the release of positive preliminary data from the open-label arm of its Phase III FLAMINGO-01 trial, which showed a statistically significant reduction in breast cancer recurrence rates. The community is actively discussing the implications of this efficacy, noting the significant endorsement from the trial's global steering committee and high levels of insider investment, fueling optimism for upcoming data presentations at the AACR annual meeting.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors weigh strong steel shipment volumes and positive free cash flow expectations against ongoing geopolitical volatility and short-term earnings headwinds. The community remains divided, with some analysts and long-term bulls highlighting potential structural tailwinds from domestic grid expansion and infrastructure demand, while others express concerns over the ongoing POSCO deal negotiations and short-term technical selling pressure.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compass Pathways is trending as the community closely monitors a pivotal clinical data readout for its COMP360 psilocybin therapy, amid significant buzz around President Trump's recent executive order to fast-track psychedelic research. Investors are actively debating the company's valuation, its competitive positioning against other biotech players in the space, and the potential impact of new regulatory tailwinds on the sector's long-term commercialization prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Cwm LLC

Cwm LLC lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.0% in the fourth quarter, according to the company in its most recent filing with the SEC...

Mirae Asset Global Investments Co. Ltd. Buys 43,302 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 703.0% during the 4th quarter, according to the company in its...

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities...

Assetmark Inc. Has $6.38 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Assetmark Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 34.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC...

GF Fund Management CO. LTD. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY

GF Fund Management CO. LTD. boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 989.1% in the fourth quarter, according to its most recent filing with the...

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday...

KBC Group NV Has $138.46 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

KBC Group NV increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 348,194 shares of the biopharmaceutical company's st...

Sumitomo Mitsui Trust Group Inc. Has $130.34 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with...

Truist Financial Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $505.00

Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating for the company in a research note on Monday...

Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Massachusetts Financial Services Co. MA lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 38.9% during the fourth quarter, according to its most recent...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.91	--	--	N/A
Q4 '25	$1.16	$0.82	-29.06%	MISSED
Q3 '25	$0.56	$1.84	228.01%	BEAT
Q2 '25	-$0.54	-$0.51	6.20%	BEAT
Q1 '25	-$0.89	-$0.44	50.56%	BEAT

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc